WO2018206565A1 - Anti-il-1r3 antibodies for use in inflammatory conditions - Google Patents

Anti-il-1r3 antibodies for use in inflammatory conditions Download PDF

Info

Publication number
WO2018206565A1
WO2018206565A1 PCT/EP2018/061846 EP2018061846W WO2018206565A1 WO 2018206565 A1 WO2018206565 A1 WO 2018206565A1 EP 2018061846 W EP2018061846 W EP 2018061846W WO 2018206565 A1 WO2018206565 A1 WO 2018206565A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
cdr
region
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2018/061846
Other languages
English (en)
French (fr)
Other versions
WO2018206565A9 (en
Inventor
Stephan Fischer
Karsten Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAB Discovery GmbH
Original Assignee
MAB Discovery GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2019561281A priority Critical patent/JP7315472B2/ja
Priority to US16/612,052 priority patent/US11639392B2/en
Priority to AU2018267092A priority patent/AU2018267092B2/en
Priority to EP18724816.6A priority patent/EP3621693A1/en
Priority to CN201880045411.9A priority patent/CN110831670A/zh
Priority to CA3062424A priority patent/CA3062424A1/en
Application filed by MAB Discovery GmbH filed Critical MAB Discovery GmbH
Publication of WO2018206565A1 publication Critical patent/WO2018206565A1/en
Anticipated expiration legal-status Critical
Publication of WO2018206565A9 publication Critical patent/WO2018206565A9/en
Priority to US18/184,759 priority patent/US20230383000A1/en
Priority to JP2023114162A priority patent/JP7605916B2/ja
Priority to AU2024202910A priority patent/AU2024202910A1/en
Priority to JP2024216380A priority patent/JP7825695B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present invention relates to methods for treating medical conditions and/or disorders characterized by uncontrolled or abnormal expression of members of the IL1R3 signaling pathway such as IL-lct, IL- ⁇ , IL-33, I L-36, I LIRA and/or I L1R3, as well as variants thereof.
  • members of the IL1R3 signaling pathway such as IL-lct, IL- ⁇ , IL-33, I L-36, I LIRA and/or I L1R3, as well as variants thereof.
  • the term also includes the neonatal receptor, FcRn, which is responsible for the transfer of materna l IgGs to the fetus (Guyer et al, J. I mmunol. 117:587 (1976) and Kim et al, J. I mmunol. 24:249 (1994)) and mediates slower catabolism, thus longer half-life.
  • FcRn neonatal receptor
  • Fc region-containing polypeptide refers to a polypeptide, such as an antibody or immunoadhesin (see definitions below), which comprises an Fc region.
  • the invention encompasses anti-ILlR3 antibody for use in the treatment of an IL1R3- mediated inflammatory condition and/or disorder in a subject.
  • the subject is a mouse and the antibody comprises a heavy chain variable (VH) region that is at least 90 % identical to the VH region of SEQ ID NO: 176, and a light chain variable (VL) region that is at least 90% identical to the VL region of SEQ I D NO: 177.
  • VH heavy chain variable
  • VL light chain variable
  • substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs).
  • the antibody that specifically binds to I L-1R3 or a fragment or derivative thereof that contains at least a portion of said antibody that is sufficient to confer I L-1R3 binding specificity binds to the same epitope as an antibody selected from the group of antibodies MAB-
  • the antibodies according to the invention have the advantage to be very potent when it comes to binding to their target. They exhibit a strong binding capacity to their antigen, IL1R3, but not to other receptors.
  • the binding properties of the antibodies were studied in biochemical enzyme- linked immunosorbent assays (ELISA) and cell binding analysis (flow cytometry) and are exemplified in Figures 2, 6 and 7.
  • the antibodies according to the invention do not only inhibit the functional activation of cytokine release in different cell lines as described above, but also in PMBCs or whole blood cells from donors. They inhibit cytokine release mediated by different specific or complex stimuli. For example, they inhibit activation of PBMCs stimulated with LPS, heat-inactivated Candida albicans, IL-12/IL-33 or anti-CD3/CD28 antibodies (cf. Fig. 14 and 15).
  • Such a pharmaceutically composition may comprise a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody that specifically binds to the IL-1R3 or a fragment or derivative thereof that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity, according to the invention.
  • pharmaceutical carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g. by injection or infusion).
  • said antibody comprises a heavy chain variable region (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from the group of VH sequences according to the invention.
  • VH heavy chain variable region
  • Example 13 Functional blockage of immune cells in whole blood
  • MSU Intraperitoneal injection
  • MAB-16-0531, 500 ⁇ g/mouse anti-I L-l 3
  • I L-IRa I L-IRa
  • Saline was used both as control for stimulation and inhibition.
  • the four groups were comprised of 4 mice as control of stimuli (Saline (inhib.) + Saline(stimuli)), 8 mice with MSU alone (Saline+MSU), 8 mice with MAB- 16-0531 + MSU) and 8 mice with I L-IRa (lOmg/kg + MSU).
  • MAB-16-0531 and I L-IRa were injected LP.
  • Fig. 22 Imiquimod psoriasis in vivo model

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2018/061846 2017-05-08 2018-05-08 Anti-il-1r3 antibodies for use in inflammatory conditions Ceased WO2018206565A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA3062424A CA3062424A1 (en) 2017-05-08 2018-05-08 Anti-il-1r3 antibodies for use in inflammatory conditions
US16/612,052 US11639392B2 (en) 2017-05-08 2018-05-08 Anti-IL-1R3 antibodies for use in inflammatory conditions
AU2018267092A AU2018267092B2 (en) 2017-05-08 2018-05-08 Anti-IL-1R3 antibodies for use in inflammatory conditions
EP18724816.6A EP3621693A1 (en) 2017-05-08 2018-05-08 Anti-il-1r3 antibodies for use in inflammatory conditions
CN201880045411.9A CN110831670A (zh) 2017-05-08 2018-05-08 用于炎性病症的抗il-1r3抗体
JP2019561281A JP7315472B2 (ja) 2017-05-08 2018-05-08 炎症症状で使用するための抗ｉｌ－１ｒ３抗体
US18/184,759 US20230383000A1 (en) 2017-05-08 2023-03-16 Anti-il-1r3 antibodies for use in inflammatory conditions
JP2023114162A JP7605916B2 (ja) 2017-05-08 2023-07-12 炎症症状で使用するための抗ｉｌ－１ｒ３抗体
AU2024202910A AU2024202910A1 (en) 2017-05-08 2024-05-02 Anti-IL-1R3 antibodies for use in inflammatory conditions
JP2024216380A JP7825695B2 (ja) 2017-05-08 2024-12-11 炎症症状で使用するための抗ｉｌ－１ｒ３抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17169953.1A EP3401332A1 (en) 2017-05-08 2017-05-08 Anti-il-1r3 antibodies for use in inflammatory conditions
EP17169953.1 2017-05-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/612,052 A-371-Of-International US11639392B2 (en) 2017-05-08 2018-05-08 Anti-IL-1R3 antibodies for use in inflammatory conditions
US18/184,759 Continuation US20230383000A1 (en) 2017-05-08 2023-03-16 Anti-il-1r3 antibodies for use in inflammatory conditions

Publications (2)

Publication Number Publication Date
WO2018206565A1 true WO2018206565A1 (en) 2018-11-15
WO2018206565A9 WO2018206565A9 (en) 2019-12-26

Family

ID=58698976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/061846 Ceased WO2018206565A1 (en) 2017-05-08 2018-05-08 Anti-il-1r3 antibodies for use in inflammatory conditions

Country Status (7)

Country Link
US (2) US11639392B2 (https=)
EP (2) EP3401332A1 (https=)
JP (3) JP7315472B2 (https=)
CN (1) CN110831670A (https=)
AU (2) AU2018267092B2 (https=)
CA (1) CA3062424A1 (https=)
WO (1) WO2018206565A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3592384A1 (en) * 2017-03-09 2020-01-15 MAB Discovery GmbH Antibodies specifically binding to human il-1r7
WO2020037154A1 (en) * 2018-08-17 2020-02-20 23Andme, Inc. Anti-il1rap antibodies and methods of use thereof
WO2020232148A1 (en) * 2019-05-13 2020-11-19 The Johns Hopkins University Macrophage diversity in regenerative, fibrotic biomaterial environments
US12043669B2 (en) 2021-05-21 2024-07-23 Leo Pharma A/S IL-1 receptor accessory protein-inhibiting antibodies and antigen-binding fragments thereof
US12502352B1 (en) 2024-06-25 2025-12-23 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies
WO2026022232A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Il-1rap inhibitor for treating or preventing hidradenitis suppurativa

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7114460B2 (ja) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
LT3684813T (lt) * 2017-09-19 2026-01-26 Mab Discovery Gmbh Agonistiniai cd40 antikūnai
CA3120474A1 (en) * 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
AR130550A1 (es) * 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
US20040214988A1 (en) 2000-03-23 2004-10-28 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
WO2005035727A2 (en) 2003-10-09 2005-04-21 Ambrx, Inc. Polymer derivatives
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
WO2010108127A1 (en) 2009-03-20 2010-09-23 Genentech, Inc. Bispecific anti-her antibodies
WO2012098407A1 (en) * 2011-01-19 2012-07-26 Cantargia Ab Anti - il1rap antibodies and their use for treating human
WO2012142391A1 (en) * 2011-04-15 2012-10-18 Merck Patemt Gmbh Anti- il-1r1 inhibitors for use in cancer
WO2015132602A1 (en) 2014-03-05 2015-09-11 Cantargia Ab Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof
WO2016020502A1 (en) * 2014-08-06 2016-02-11 Cantargia Ab Novel antibodies and uses thereof
WO2016207304A2 (en) * 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5283179A (en) 1990-09-10 1994-02-01 Promega Corporation Luciferase assay method
DK0488470T3 (da) 1990-11-26 1997-12-22 Akzo Nobel Nv Fremgangsmåde til fremstilling af antistoffer
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US6280955B1 (en) 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
WO2002064630A2 (en) 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein
US20030049255A1 (en) 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
US20090215895A1 (en) 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
EP1910513B1 (en) 2005-07-01 2016-08-10 John Schrader Methods of isolating antibody secreting cells from blood samples of immunized animals and generating monoclonal antibodies from said antibody secreting cells.
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
WO2009120905A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
SI2400298T1 (sl) 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
WO2014100772A1 (en) 2012-12-21 2014-06-26 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
WO2014113433A1 (en) 2013-01-16 2014-07-24 George Mason University Binding domain mapping
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US20040214988A1 (en) 2000-03-23 2004-10-28 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
WO2005035727A2 (en) 2003-10-09 2005-04-21 Ambrx, Inc. Polymer derivatives
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
WO2010108127A1 (en) 2009-03-20 2010-09-23 Genentech, Inc. Bispecific anti-her antibodies
WO2012098407A1 (en) * 2011-01-19 2012-07-26 Cantargia Ab Anti - il1rap antibodies and their use for treating human
WO2012142391A1 (en) * 2011-04-15 2012-10-18 Merck Patemt Gmbh Anti- il-1r1 inhibitors for use in cancer
WO2015132602A1 (en) 2014-03-05 2015-09-11 Cantargia Ab Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof
WO2016020502A1 (en) * 2014-08-06 2016-02-11 Cantargia Ab Novel antibodies and uses thereof
WO2016207304A2 (en) * 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
BARBAS ET AL., PROC NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813
BARDIN THOMAS: "Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence", JOINT BONE SPINE, vol. 82, 2015, 2015, XP029367178, ISSN: 1297-319X, DOI: 10.1016/S1297-319X(15)30003-8 *
CAPEL ET AL., IMMUNOMETHODS, vol. 4, 1994, pages 25 - 34
CHIN, J.W. ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, 2002, pages 9026 - 9027
CHIN, J.W. ET AL., PICAS UNITED STATES OF AMERICA, vol. 99, 2002, pages 11020 - 11024
CHIN, J.W.; SCHULTZ, P.G., CHEMBIOCHEM, vol. 11, 2002, pages 1135 - 1137
DAERON, ANNU. REV. IMMUNOL., vol. 15, 1997, pages 203 - 234
DAERON, M., ANNU. REV. IMMUNOL., vol. 15, 1997, pages 203 - 234
DAVIS ET AL., IMMUNOLOGICAL REVIEWS, vol. 190, 2002, pages 123 - 136
DE HAAS ET AL., J. LAB. CHN. MED., vol. 126, 1995, pages 330 - 41
EDELMAN ET AL., PROC NATL ACAD SCI USA, vol. 63, 1969, pages 78 - 85
EMILY B CULLINAN ET AL: "IL-1 Receptor Accessory Protein Is an Essential Component of the IL-1 Receptor", THE JOURNAL OF IMMUNOLOGY, 15 November 1998 (1998-11-15), UNITED STATES, pages 5614, XP055486650, Retrieved from the Internet <URL:http://www.jimmunol.org/content/jimmunol/161/10/5614.full.pdf> *
GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587
HAAS ET AL., J. LAB. CLIN. MED., vol. 126, 1995, pages 330 - 41
HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896
HUANG J. ET AL., PNAS USA, vol. 94, 1997, pages 12829 - 12832
HUSTON, J.S., METHODS IN ENZYMOL., vol. 203, 1991, pages 46 - 88
INDRA-GUSTI MANSUR ET AL: "Engagement of IL-1 receptor accessory protein (IL-1RAcP) with the monoclonal antibody AY19 provides co-activating signals and prolongs the CD2-induced proliferation of peripheral blood lymphocytes", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 139, no. 1, 30 April 2011 (2011-04-30), pages 52 - 57, XP028246918, ISSN: 0165-2478, [retrieved on 20110511], DOI: 10.1016/J.IMLET.2011.04.015 *
JACKSON ET AL., J. IMMUNOL., vol. 1 54, no. 7, 1995, pages 3310 - 9
JEFFERIS ET AL., IMMUNOL LETT, vol. 82, 2002, pages 57 - 65
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249
MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
RAVETCH; KINET, ANNU. REV. IMMUNOL, vol. 9, 1991, pages 457 - 492
RAVETCH; KINET, ANNU. REV. IMMUNOL, vol. 9, 1991, pages 457 - 92
SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155
WANG, L.; SCHULTZ, P.G., CHEM, 2002, pages 1 - 10
WINDHEIM M. ET AL., MOL. CELL. BIOL., vol. 28, 2008, pages 1783 - 1791
XIAOXIA L. ET AL., MOL. CELL, BIOL., vol. 19, 1999, pages 4643 - 4652
YELTON ET AL., J. IMMUNOL., vol. 1, no. 55, 1995, pages 1994 - 2004
ZHAO KAI ET AL: "[Construction of hybridoma cells with IL1RAP as a new marker for leukemia stem cells and detection of its monoclonal antibody]", ZHONGGUO SHIYAN XUEYEXUE ZAZHI - JOURNAL OF EXPERIMENTALHEMATOLOGY, ZHONGGUO SHIYAN, XUEYEXUE ZAZHISHE, BEIJING, CN, vol. 21, no. 6, 1 December 2013 (2013-12-01), pages 1390 - 1393, XP009186185, ISSN: 1009-2137, DOI: 10.7534/J.ISSN.1009-2137.2013.06.005 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3592384A1 (en) * 2017-03-09 2020-01-15 MAB Discovery GmbH Antibodies specifically binding to human il-1r7
US11352432B2 (en) 2017-03-09 2022-06-07 Mab Discovery Gmbh Antibodies specifically binding to human IL-1R7
EP3592384B1 (en) * 2017-03-09 2025-07-02 MAB Discovery GmbH Antibodies specifically binding to human il-1r7
WO2020037154A1 (en) * 2018-08-17 2020-02-20 23Andme, Inc. Anti-il1rap antibodies and methods of use thereof
US11168140B2 (en) 2018-08-17 2021-11-09 23Andme, Inc. Anti-IL1RAP antibodies
US12304959B2 (en) 2018-08-17 2025-05-20 23Andme, Inc. Method of treating asthma with anti-IL1RAP antibodies
WO2020232148A1 (en) * 2019-05-13 2020-11-19 The Johns Hopkins University Macrophage diversity in regenerative, fibrotic biomaterial environments
US12043669B2 (en) 2021-05-21 2024-07-23 Leo Pharma A/S IL-1 receptor accessory protein-inhibiting antibodies and antigen-binding fragments thereof
US12502352B1 (en) 2024-06-25 2025-12-23 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies
WO2026022232A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Il-1rap inhibitor for treating or preventing hidradenitis suppurativa

Also Published As

Publication number Publication date
AU2018267092A1 (en) 2019-11-14
CA3062424A1 (en) 2018-11-15
EP3621693A1 (en) 2020-03-18
JP7825695B2 (ja) 2026-03-06
US20230383000A1 (en) 2023-11-30
AU2018267092B2 (en) 2024-02-08
EP3401332A1 (en) 2018-11-14
JP2025038044A (ja) 2025-03-18
WO2018206565A9 (en) 2019-12-26
JP2023134618A (ja) 2023-09-27
AU2024202910A1 (en) 2024-05-23
US11639392B2 (en) 2023-05-02
US20200140559A1 (en) 2020-05-07
JP7315472B2 (ja) 2023-07-26
JP2020519590A (ja) 2020-07-02
JP7605916B2 (ja) 2024-12-24
CN110831670A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
US20230383000A1 (en) Anti-il-1r3 antibodies for use in inflammatory conditions
US12024564B2 (en) Humanized anti-IL-1R3 antibodies
HK40116833A (en) Humanized anti-il-1r3 antibodies
HK40003550B (en) Humanized anti-il-1r3 antibodies
HK40003550A (zh) 人源化抗il-1r3 抗体
EA049751B1 (ru) Гуманизированные анти-il-1r3 антитела
EA040391B1 (ru) Гуманизированные анти-il-1r3 антитела

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18724816

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3062424

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019561281

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018267092

Country of ref document: AU

Date of ref document: 20180508

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018724816

Country of ref document: EP

Effective date: 20191209